期刊文献+

Ⅲ度房室传导阻滞患者植入不同模式起搏器前后BNP水平变化分析 被引量:3

The Influence of Different Cardiac Pacing Modes on Plasma Levels of B-Type Natriuretic Peptide in Patients with Ⅲ°AVB
下载PDF
导出
摘要 目的:评价Ⅲ度房室传导阻滞患者在植入不同模式永久起搏器前后脑钠素(BNP)水平变化。方法:研究对象为2006~2008年我院因Ⅲ度房室传导阻滞植入永久起搏器的患者,排除有明确冠心病、心房颤动、瓣膜病、贫血、射血分数小于50%、完全左束支传导阻滞的病例。共入选84名患者,其中男性48名(57.1%),女性36名(42.9%)。所有患者术前检测BNP水平。其中66例植入DDDR永久起搏器,18例患者植入VVIR永久起搏器。于术后1个月及6个月再次检测BNP水平。结果:Ⅲ度房室传导阻滞患者术前BNP水平为(497±41)pg/ml。植入起搏器后1个月,两组BNP水平均明显下降[(495±39]pg/s]vs(141±26)pg/ml,P<0.05,DDDR组;(502±45)pg/ml vs(181±22)pg/ml,P<0.05],VVIR组,其中DDDR组BNP水平更低。6个月后,DDDR组BNP水平无明显变化[(151±11)pg/ml vs(141±)26pg/ml,P>0.5],VVIR组BNP水平有所上升[(242±24)pg/ml vs(181±22)pg/ml,P<0.05]。结论:Ⅲ度房室传导阻滞患者BNP水平较高。植入永久超搏器后使BNP水平下降,植入DDDR起搏器的患者较VVIR的患者更加明显。随植入时间的延长,植入VVIR的患者BNP水平有上升趋势。 Objective:The aim of the study was to assess the level of BNP in Ⅲ°AVB patients, and the changes of plasma BNP after implored different model permanent cardia pacing, Methods:84 patients with Ⅲ° AVB undergoing routine pacemaker implantation were enrolled. There were 18 patients with VVIR pacing mode, and 66 patients with DDDR pacing mode implanted. The BNP levels of patients with permanent carchae pacing were assayed before pacemaker implantation, I month and 6 months postoperatively. Results:The level of BNP m patients with Ⅲ°AVB was (497 ± 41)pg/ ml.During 1 month follow-up, the BNP levels decreased, more significantly in DDDR group. During 6 months follow-up no significant changes in BNP level, while the BNP level increased in VVIR group. Conclusion: The plasma BNP level in Ⅲ°AVB patients was higher than normal. The advantage of physiologic pacing in BNP levels became significantly since 6 months postoperatively.
出处 《中国医药导刊》 2009年第10期1651-1652,共2页 Chinese Journal of Medicinal Guide
关键词 Ⅲ度房室传导阻滞 BNP 永久起搏器 Ⅲ°AVB B-type natriuretic peptide permanent pacemaker
  • 相关文献

参考文献3

二级参考文献43

  • 1Van Cheng BS, Kazanegra R, Garcia A,et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure[J]. J Am Coll Cardiol, 2001,37:386-391.
  • 2Grantham JA, Burnett JC. BNP, Increasing importance in the pathophysiology and diagnosis of congestive heart failure[J]. Circulation, 1997,96:388-390.
  • 3Mann DL. Mechanisms and models of heart failure : A combinatorial approach[J]. Circulation, 1999,100 : 999-1008.
  • 4Kazanegra R, Van Cheng BS, Garcia A,et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure:Apilot study[J]. J Cardiac Fail, 2001, 7:21-29.
  • 5Maeda K, Tsutamoto T, Wada A,et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure[J]. J Am Coil Cardiol, 2000,36:1587-1593.
  • 6Richards AM, Doughty R, Nicholls MG,et al. for the Australia-New Zealand Heart Failure Group: Neurohumoral predictors of benefit from earvedilol in isehemie left ventricular dysfunction[J]. Circulation, 1999,99: 786-797.
  • 7Troughton RW, Frampton CM, Yandle TG ,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide concentrations[J]. Lancet, 2000, 355 : 1125-1130.
  • 8Maisel. B-type natriuretic peptide in the diagnosis and management of congestive heart failure [J]. Heart Failure. 2001,19:557-571.
  • 9Vinson JM, Rich MW, Sperry JC,et al. Early readmission of elderly patients with heart failure[J]. J Am Geriatr Soc,1990, 38:1290-1295,.
  • 10Adams KF. Post hoc subgroup analysis and the truth of a clinical trial[J]. Am Heart J, 1998, 136:751-758.

共引文献21

同被引文献21

  • 1孙育民,王骏,严铭钰,王鸣和.右室心尖部起搏前后心功能水平的对比研究[J].中国心脏起搏与心电生理杂志,2004,18(6):418-418. 被引量:6
  • 2Nahlawi M,Waligom M,Spies SM,et al.Left ventricular fimction during and after right vontricular pacing[J].J Am Coil Cardiol,2004;44:1883.
  • 3Wilkoff BL,Cook JR,Epstein AE,et al. Dual chamber pacing or ventricular back- up pacing in pacients with as implantable defibrillator:the dual chamber and VV1 implantable defibrillator(DAVID) trial[J]. JAMA,2002;288:3115.
  • 4Greco OT, Bittencourt LR, Vargas RN, et al. Sleep parameters in patients using pacemakers with sleep rate function on[J].Pacing Clin Electrophysi ol,2006;29(2): 135 - 41.
  • 5Nahlawi M,Waligom M,Spies SM,et al.Left ventricular function during and afterright vontricular pacing[J]J Am Coil Cardiol,2004;44:1883.
  • 6Wilkoff BL,Cook JR,Epstein AE,et al. Dual chamber pacing or ventricular back-up pacing in pacients with as implantable defibrillator:the dual chamber and VV1implantable defibrillator(DAVID) trial[J]. JAMA,2002;288:3115.
  • 7Greco OT, Bittencourt LR, Vargas RN, et al. Sleep parameters in patientsusing pacemakers with sleep rate fuLction on[J].Pacing Clin Electrophysiol,2006;29(2):135-141.
  • 8Kannel W B,Abbott R D,Savage D D,et al.EPidemidogic featuresof chronic atrialfibrihation,The Framingham Study[J].N Engl J med,1978,306(1):1018-1025.
  • 9Benjamn E J,Wolf P A D A,Gostino R B,et al.Impaet ofartialfibrilletion on the risk of death the Framinghem heart study[J].Circulation,1998,98(1):946-952.
  • 10Healey J S,Toff W D,Lamas G A,et al.Cardiovascular outcomeswith atrial based pacing compared with ventricular pacing:metaanalysis of randomized trials,using individual patient data [J].Circulation,2006,114(1):11-17.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部